Mineralys Therapeutics, Inc. (MLYS): Cash & Equivalents
$172.92M
As of 2025-12-31
$138.27M
As of 2026-06-30
+25.4%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $172.92M | +51.6% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $114.09M | +131.4% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $49.30M | -43.8% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $87.70M | n/a | 2024-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | 2025-12-31 | $172.92M | +51.6% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $246.96M | +124.5% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $165.81M | +521.6% |
Compare MLYS, PTGX, AMRN, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗